Schrödinger is expected to report Q2 2026 revenue of $47.2 million and a consensus EPS loss of $0.60, with the stock currently trading at $15.14 against an average analyst target of $20.57.
The primary focus for investors remains the company's aggressive transition toward a hosted software licensing model and the potential market impact of its new Bunsen AI co-scientist tool.
Recent results have shown margin pressure as hosted software adoption grows, though this shift is expected to provide more stable long-term recurring revenue. Market participants are also closely monitoring any updates on the proprietary drug discovery pipeline and milestone payments from key partners like Novartis.